Teva has announced that R. Ananthanarayanan – known as Ananth – is to rejoin the company as CEO of its active pharmaceutical ingredients business after taking leading roles at Cipla and Strides in recent years. Meanwhile, Strides has disclosed a change of chief operating officer coming next year, while Civica Rx has named a manager for its sterile injectables operations.
Teva has announced that its former active pharmaceutical ingredient and biologics operations chief of several years ago, R. Ananthanarayanan, is to rejoin the company as CEO of its Teva API business from 27 November. He will be based out of Teva’s US headquarters in Parsippany, New Jersey.
Ananthanarayanan – also known as Ananth – has served in multiple high-profile roles since leading the former Teva API and...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Steffen Wagner has taken over as Stada’s head of Germany, adding to his existing responsibilities in Europe, after Eelco Ockers stepped down from the role. Ockers’ departure comes as German generics giant Stada restructures its business to bring its branded and consumer health interests into closer alignment as part of a more streamlined model.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
